IRIS
SCHENONE, ANGELO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 29.085
Totale 29.085
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 29.085
Totale 29.085
Salva come PNG Salva come JPEG
Città #
Genova 20.049
Rapallo 3.110
Genoa 3.091
Vado Ligure 2.742
Bordighera 93
Totale 29.085
Salva come PNG Salva come JPEG
Nome #
Consistence and discrepancy of neuropathic pain screening tools DN4 and ID-Pain. 172
Hereditary motor and sensory neuropathy with myelin outfolding: clinical, genetic and neuropathological study of three cases 158
Experimental Charcot-Marie-Tooth type 1A: A cDNA microarrays analysis 157
Dysimmune mononeuropathies: A diagnosis not to be missed 154
Reliability of clinical outcome measures in Charcot-Marie-Tooth disease. 153
Does parkin play a role in the peripheral nervous system? A family report 151
Sphingomyelin as a myelin biomarker in CSF of acquired demyelinating neuropathies 151
Autologous stem cell transplantation as rescue therapy in malignant forms of multiple sclerosis. 150
Autoimmune central diabetes insipidus in a patient with ureaplasma urealyticum infection and review on new triggers of immune response. 150
17p11.2 duplication is a common finding in sporadic cases of charcot-marie-tooth type 1 150
Intravenous immunoglobulin versus intravenous methylprednisolone for chronic inflammatory demyelinating polyradiculoneuropathy: a randomised controlled trial. 148
Hereditary motor and sensory neuropathy with deafness, mental retardation and absence of large myelinated fibers. 147
Clinical epidemiology of ALS in Liguria, Italy. 147
The diadenosine homodinucleotide P18 improves in vitro myelination in experimental Charcot-Marie-Tooth type 1A 147
Early abnormalities in sciatic nerve function and structure in a rat model of Charcot-Marie-Tooth type 1A disease. 144
A novel mutation of GDAP1 associated with Charcot-Marie-Tooth disease in three Italian families: evidence for a founder effect 142
Relapses after treatment with rituximab in a patient with multiple sclerosis and anti myelin-associated glycoprotein polyneuropathy. 142
Intense immunosuppression followed by autologous stem cell transplantation in severe multiple sclerosis. 142
Direct immunofluorescence in sural nerve biopsies. 141
Sural nerve biopsy and functional studies support the pathogenic role of a novel MPZ mutation. 141
Underexpression of messenger RNA for peripheral myelin protein 22 in hereditary neuropathy with liability to pressure palsies 140
Impairment of central motor conduction in diabetic patients. 139
Mycophenolate mofetil in dysimmune neuropathies: a preliminary study. 139
Alterations in the Arf6-regulated plasma membrane endosomal recycling pathway in cells overexpressing the tetraspan protein Gas3/PMP22 137
Charcot-Marie-Tooth (CMT) 1a duplication at 17p11.2 in Italian families. 137
A novel compound heterozygous mutation ofC20orf54gene associated with Brown-Vialetto-Van Laere syndrome in an Italian family 137
Natural history of CMT1A including QoL: a 2-year prospective study. 136
HSPB1 and HSPB8 in inherited neuropathies: study of an Italian cohort of dHMN and CMT2 patients 136
Peripheral Nerve Society Guideline on processing and evaluation of nerve biopsies. 136
GFAP expression of human Schwann cells in tissue culture. 134
Variables influencing quality of life and disability in Charcot Marie Tooth (CMT) patients: Italian multicentre study. 133
147th ENMC International Workshop: Guideline on processing and evaluation of sural nerve biopsies, 15-17 December 2006, Naarden, The Netherlands. 133
Phenotypic characterization of hypomyelination and congenital cataract 133
An Italian family with Ala-47 transthyretin mutation associated with cardiomyopathy and polyneuropathy. 133
Sonography of the median nerve in Charcot-Marie-Tooth disease 133
Levodopa-induced neutropenia. 133
A cross-sectional study investigating frequency and features of definitely diagnosed diabetic painful polyneuropathy 133
Tolerability and efficacy study of P2X7 inhibition in experimental Charcot-Marie-Tooth type 1A (CMT1A) neuropathy 133
Ascorbic acid in Charcot-Marie-Tooth disease type 1A (CMT-TRIAAL and CMT-TRAUK): a double-blind randomised trial. 132
PMP22 transgenic dorsal root ganglia cultures show myelin abnormalities similar to those of human CMT1A. 132
Progressive sensory-motor polyneuropathy with tomaculous changes is associated to 17p11.2 deletion. 132
Mifepristone (RU 38486) influences expression of glycoprotein Po and morphological parameters at the level of rat sciatic nerve: In vivo observations . 131
Acute axonal form of Guillain-Barre syndrome in a multiple sclerosis patient: chance association or linked disorders? 131
An abnormal mRNA produced by a novel PMP22 splice site mutation associated with HNPP 131
The D355V mutation decreases EGR2 binding to an element within the Cx32 promoter. 130
Charcot-Marie-Tooth and pain: correlations with neurophysiological, clinical, and disability findings. 130
High-dose Ig VENA is well tolerated and efficacious in patients with multifocal motor neuropathy 130
Hand Rehabilitation Treatment for Charcot-Marie-Tooth Disease: An Open Label Pilot Study 130
A nationwide retrospective analysis on the effect of immune therapies in patients with chronic inflammatory demyelinating polyradiculoneuropathy 129
GDAP1 mutation in autosomal recessive Charcot-Marie-Tooth with pyramidal features. 128
Impairment of PMP22 transgenic Schwann cells differentiation in culture: implications for Charcot-Marie-Tooth type 1A disease. 127
Multifocal motor neuropathy with conduction block after Campylobacter jejuni enteritis. 127
Progressive multifocal leukoencephalopathy in an adult patient with ICF syndrome 126
Rituximab in patients with chronic inflammatory demyelinating polyradiculoneuropathy: a report of 13 cases and review of the literature. 126
Dopamine-agonist responsive Parkinsonism in a patient with the SANDO syndrome caused by POLG mutation. 126
Insulin treatment enhances expression of IGF-I in sural nerves of diabetic patients. 126
Innovative quantitative testing of hand function in Charcot-Marie-Tooth neuropathy 126
Responsiveness of clinical outcome measures in Charcot-Marie-Tooth disease 126
Monitoring effectiveness and safety of Tafamidis in transthyretin amyloidosis in Italy: a longitudinal multicenter study in a non-endemic area 125
Deficiency of hyccin, a newly identified membrane protein, causes hypomyelination and congenital cataract 125
Gain of glycosylation: a new pathomechanism of Myelin Protein Zero mutations 124
AN IN VITRO MODEL OF MYELIN PROTEIN ZERO MUTATIONS IN SCHWANN CELLS 124
Correlation between clinical/neurophysiological findings and quality of life in Charcot-Marie-Tooth type 1A. 124
Influence of comorbidities on the phenotype of patients affected by Charcot–Marie–Tooth neuropathy type 1A 124
Molecular diagnosis of hereditary neuropathy with liability to pressure palsies (HNPP) by detection of 17p11.2 deletion in Italian patients. 124
Guillain-Barré syndrome following chickenpox: A case series 123
WERNICKE-KORSAKOFF ENCEPHALOPATHY FOLLOWING BILIOPANCREATIC DIVERSION 123
Mitichondrial dysfunction in experimental Charcot-marie-Tooth type 1° (CMTIA) neuropathy: a possible key factor for the axonal degeneration 122
Different cellular and molecular mechanisms for early and late-onset myelin protein zero mutations 122
B-cell-activating factor in rituximab-treated patients with anti-MAG polyneuropathy. 122
Inherited Peripheral Neuropathies 122
GDAP1 mutations in Italian axonal Charcot-Marie-Tooth patients: Phenotypic features and clinical course 122
Alternative Splicing in the Human PMP22 Gene: Implications in CMT1A Neuropathy 122
Takotsubo cardiomyopathy and torsade de pointes in myasthenic crisis: be aware of QT prolongation 122
Sjögren’s syndrome associated chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) treated with autologous and subsequently allogeneic haematopoietic SCT (HSCT) 121
Psychological considerations in the assessment and treatment of pain in neurorehabilitation and psychological factors predictive of therapeutic response: Evidence and recommendations from the Italian consensus conference on pain in neurorehabilitation 121
Soluble Neuregulin1 is strongly up-regulated in the rat model of Charcot-Marie-Tooth 1A disease 121
Evaluation of the psychometric properties of the EORTC chemotherapy-induced peripheral neuropathy questionnaire (QLQ-CIPN20) 121
Bannwarth syndrome: report of two cases 120
Use of cosH1 probe in hereditary neuropathy with liability to pressure palsies: a reliable genetic test for demonstration of identical size of 17p11.2 deletion in unrelated patients. 120
Axonal damage and demyelination in long-term dorsal root ganglia cultures from a rat model of Charcot-Marie-Tooth type 1A disease 120
Mutation update for myelin protein zero-related neuropathies and the increasing role of variants causing a late-onset phenotype 120
Long-term effect of rituximab in anti-mag polyneuropathy 119
Peripheral nerve abnormalities 119
Both Schwann cell and axonal defects cause motor peripheral neuropathy in Ebf2-/- mice. 119
Randomised controlled trial of methotrexate for chronic inflammatory demyelinating polyradiculoneuropathy (RMC trial): a pilot, multicentre study. 119
Severe neuropathy after Diphtheria-Tetanus-Pertussis vaccination in a child carrying a novel frame-shift mutation in the small haet-shock protein 27 gene (HSPB1). 119
A case of secondary syphilis presenting as optic neuritis 118
Class II antigen expression on human cultured Schwann cells from patients with Charcot-Marie-Tooth disease. 118
Synaptopodin and 4 novel genes identified in primary sensory neurons. 118
Impaired expression of ciliary neurotrophic factor in Charcot-Marie-Tooth type 1A neuropathy 118
A novel mutation in the N-terminal acting-binding domain of Filamin C protein causing a distal myofibrillar myopathy 118
Patients' and physicians' interpretation of chemotherapy-induced peripheral neurotoxicity 118
Early electophysiological changes in transgenic rat model of charcot-marie-tooth. 117
Rituximab efficacy in CIDP associated with idiopathic thrombocytopenic purpura 117
The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings. 117
Rasch-Transformed Total Neuropathy Score clinical version (RT-TNSc©) in patients with chemotherapy-induced peripheral neuropathy 117
Responsiveness of gait analysis parameters in a cohort of 71 CMT subjects 116
l-Acetyl-carnitine in Patients with Carpal Tunnel Syndrome: Effects on Nerve Protection, Hand Function and Pain 115
Peripheral neuropathy in Cockayne syndrome. 115
Totale 13.049
Salva come PNG Salva come JPEG
Categoria #
all - tutte 99.772
article - articoli 92.839
book - libri 0
conference - conferenze 6.360
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 573
Totale 199.544
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20205.554 0 0 0 0 0 856 1.257 581 703 1.164 714 279
2020/20212.346 166 205 194 285 122 174 208 224 195 252 158 163
2021/20223.635 121 259 308 425 131 207 202 826 188 331 134 503
2022/20233.735 370 338 37 380 612 628 28 247 622 28 389 56
2023/20242.412 129 263 93 328 171 417 214 163 114 68 129 323
2024/20253.049 307 482 247 482 892 639 0 0 0 0 0 0
Totale 29.683